Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov page footer now displays software revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check11 days agoChange DetectedThe clinical trial record for a Phase 2 study of Telomelysin (OBP-301) with pembrolizumab in esophagogastric adenocarcinoma is displayed, with study design, participant criteria, outcome measures, locations, and record history.SummaryDifference49%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedA general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the blocked study page. The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the full study record with a minimal header and Home link, and the previously visible trial details are no longer accessible on this page.SummaryDifference18%

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.